Literature DB >> 11481316

Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients.

B Byl, D Baran, F Jacobs, A Herschuelz, J P Thys.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11481316     DOI： 10.1093/jac/48.2.325

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  13 in total

1.  Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection.

Authors:  Olanrewaju O Okusanya; Sujata M Bhavnani; Jeffrey Hammel; Predrag Minic; Lieven J Dupont; Alan Forrest; Geert-Jan Mulder; Constance Mackinson; Paul G Ambrose; Renu Gupta
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 2.  Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

Authors:  Charlotte Roy; Manon Launay; Sophie Magréault; Isabelle Sermet-Gaudelus; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

3.  Antipseudomonal agents exhibit differential pharmacodynamic interactions with human polymorphonuclear leukocytes against established biofilms of Pseudomonas aeruginosa.

Authors:  Athanasios Chatzimoschou; Maria Simitsopoulou; Charalampos Antachopoulos; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

Review 4.  Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters.

Authors:  Sofia K Kasiakou; Kenneth R Lawrence; Nicolaos Choulis; Matthew E Falagas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.

Authors:  William A Prescott; Allison E Gentile; Jerod L Nagel; Rebecca S Pettit
Journal:  P T       Date:  2011-11

6.  Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.

Authors:  Timothy J Bensman; Joshua Wang; Jordanna Jayne; Lynn Fukushima; Adupa P Rao; David Z D'Argenio; Paul M Beringer
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 7.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

8.  Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia.

Authors:  Cassio Girardi; Marc Tonnellier; Ivan Goldstein; Alfonso Sartorius; Frederic Wallet; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2006-07-21       Impact factor: 17.440

9.  Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis.

Authors:  Lisa T Hong; Theodore G Liou; Rishi Deka; Jordan B King; Vanessa Stevens; David C Young
Journal:  Chest       Date:  2018-06-13       Impact factor: 9.410

10.  Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis.

Authors:  J Riethmueller; S Junge; T W Schroeter; K Kuemmerer; P Franke; M Ballmann; A Claass; S Broemme; R Jeschke; A Hebestreit; D Staab; K Koetz; G Doering; M Stern
Journal:  Infection       Date:  2009-09-05       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.